Skip to main content

Brain Ischemia

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
2 programs
2
CilostazolPhase 41 trial
cilostazolPhase 41 trial
Active Trials
NCT01013532Unknown1,600Est. Dec 2016
NCT02483169Unknown800Est. Dec 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
Aggressive BP loweringPhase 41 trial
Active Trials
NCT01104311Terminated132Est. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerAggressive BP lowering
OtsukaCilostazol
Otsukacilostazol

Clinical Trials (3)

Total enrollment: 2,532 patients across 3 trials

NCT01104311PfizerAggressive BP lowering

Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis

Start: Apr 2010Est. completion: Dec 2015132 patients
Phase 4Terminated
NCT01013532OtsukaCilostazol

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

Start: Jun 2009Est. completion: Dec 20161,600 patients
Phase 4Unknown
NCT02483169Otsukacilostazol

PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study

Start: Jun 2009Est. completion: Dec 2016800 patients
Phase 4Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.